News Releases

CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment Private Placement Financing of $53.6 million in Gross Proceeds with Top-Tier Healthcare Investors Strategic Partnership and Exclusive Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Tildacerfont for CAH in Japan

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 28, 2023-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 9, 2023-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 1, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier

Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated in 2H 2023 Amendment to Phase 2 CAHptain Clinical Trial in Pediatric Classic CAH Enhances Study Design; Topline Data from Adolescents Anticipated in 2H 2023 Topline Data in Phase 2 P.O.W.E.R.

Partnership aims to accelerate global development and commercialization plans for tildacerfont to address worldwide unmet medical need in congenital adrenal hyperplasia (CAH) Deal advances strategy to partner tildacerfont commercial rights outside the United States Spruce to receive $15 million